logo
calendar25 Noyabr 2019
view76
Main language:Uzbek

THE PLACE OF RE-TRANSURETHRAL RESECTION IN THE SURGICAL TREATMENT OF BLADDER CANCER

Field of Science:
pdf

file.pdf

PDF

Биомедицина ва амалиёт журнали

Биомедицина ва амалиёт журнали

Publish Articlesee more

ARTICLE ANNOTATION

quote
Purpose: Development of prevention of recurrence of muscular non-invasive bladder cancer after transurethral resection. Materials and methods: In the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, the results of surgical treatment of 72 patients with muscular non-invasive bladder cancer for the period 2014-2016 were retrospectively studied. There were 27 women (37.5%), men 45 (62.5%), average age 62 ± 2.4 years. Median observation 26 months with stage T1N0M0. Patients were divided into 2 groups. Group № 1 included patients who received standard treatment (TUR + intravesical monochemotherapy), and group № 2 included TUR + ReTUR + intravesical monochemotherapy. Results: The relapse-free overall survival in both groups is not statistically significant, that is, there is no difference, p = 0.353. This can be explained by the heterogeneity of patients in groups. In the group with low risk in patients who underwent ReTUR, the statistical significance is higher in the rates of relapse-free survival than in the control group. At the same time, at high risk, again, we did not notice statistical differences in the comparative groups (p = 0.314). Conclusion: Summarizing the above, we can say that ReTUR in muscular noninvasive bladder cancer reduces the likelihood of early recurrence, has more informativeness in the re-placement of the disease. ReTUR is a multifunctional surgical intervention and is recommended to be used in everyday practice in the treatment of this disease.

AUTHORS

N.Rakhimov

R.Khoshimov

S.Khayitboeva

Tags

# ковук саратони# рецидив# трансуретрал резекция# рак мочевого пузыря# трансуретральная резекция# bladder cancer# recurrence# transurethral resection

OTHER ARTICLES IN THIS JOURNAL

Rate Article

0
0 ratings
5
4
3
2
1

Article Identifiers

ROI:

https://eroi.uz/11.0037/A1119-0193

DOI:

Not Available

References

1. Pereverzev, A. S., & Petrov, S. B. (2002). Opuholi mochevogo puzyrya [Bladder Tumors]. Har’kov.

2. Figurin, K. M. (2006). Vnutripuzyrnaya himioterapiya bol’nyh poverhnostnym rakom mochevogo puzyrya: vozmozhnosti povysheniya ehffektivnosti i perspektivy [Intravesical chemotherapy for patients with superficial bladder cancer: possibilities for increasing efficiency and prospects]. Onkourologiya, (3).

3. Seregin I. V., Matveev V. B., Figurin K. M. Effektivnost’ podderzhivayushchej vnutripuzyrnoj immunoterapii vakcinoj BCJ posle transuretral’noj rezekcii pri poverhnostnom rake mochevogo puzyrya [Efficacy of supportive intravesical immunotherapy with BCG vaccine after transurethral resection for superficial bladder cancer]. Mater. III kongr. Ros. obshchestva onkourologov.— M., 2008.— S. 116–117.

4. M. N. Tillyashajhov, M. I. Boltaev, D. K. Abdurahmanov, E. V. Kolesnikova Osobennosti klinicheskogo techeniya i proyavleniya raka mochevogo puzyrya [Features of the clinical course and manifestations of bladder cancer]. Materialy VI kongr. Ros. o-va onkourologov (Moskva, 5-7 okt. 2011 g.). – M., 2011. – S. 197-198

5. Tillyashajhov M.N., Boltaev M.I., Hasanov SH.T., EHrgashev O.N., Kolesnikova E.V. Osobennosti techeniya raka mochevogo puzyrya u lic molodogo vozrasta [Features of the course of bladder cancer in young people]. Materialy V kongressa Rossijskogo obshchestva onkourologov. Moskva, 6-8 oktyabrya 2010 g. - S.160-161.

6. Tillyashajhov M.N., Hodzhibekova YU.M., Boltaev M.I., Hasanov SH.T., Abdurahmanov D.K., Ergashev O.N. Znachenie magnitno-rezonansnoj tomografii pri opuholyah mochevogo puzyrya [Magnetic Resonance Imaging for Bladder Tumors]. Sbornik trudov VIII nauchno-prakticheskoj konferencii radiologov Uzbekistana. Sovremennye metody medicinskoj vizualizacii i intervencionnoj radiologii. Tashkent, 22-23 aprelya 2010 g. -S.269.

7. M.N. Tillyashajhov, M.I. Boltaev, D.K. Abdurahmanov, E.V. Kolesnikova Osobennosti klinicheskogo techeniya i proyavleniya raka mochevogo puzyrya [Features of the clinical course and manifestations of bladder cancer]. Materialy V kongressa Rossijskogo obshchestva onkourologov. Moskva, 6-8 oktyabrya 2010 g. - S.160-161.

8. Babjuk, M., Böhle, A., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., ... & van Rhijn, B. W. (2017). EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. European urology, 71(3), 447-461.

9. Egbers, L., Grotenhuis, A. J., Aben, K. K., Alfred Witjes, J., Kiemeney, L. A., & Vermeulen, S. H. (2015). The prognostic value of family history among patients with urinary bladder cancer. International journal of cancer, 136(5), 1117-1124.

10. Kamat, A. M., & Orten, S. (2014). Myths and mysteries surrounding bacillus CalmetteGuérin therapy for bladder cancer. European urology, 65(2), 267

11. Smith, S. C., Baras, A. S., Lee, J. K., & Theodorescu, D. (2010). The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer research, 70(5), 1753-1758.